Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies.

IF 2.3 4区医学 Q3 ONCOLOGY

Current cancer drug targets Pub Date : 2024-01-01 DOI:10.2174/1568009623666230712095021

Xintong Peng, Jingfan Zheng, Tianzi Liu, Ziwen Zhou, Chen Song, Yan Geng, Zichuan Wang, Yan Huang

{"title":"Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies.","authors":"Xintong Peng, Jingfan Zheng, Tianzi Liu, Ziwen Zhou, Chen Song, Yan Geng, Zichuan Wang, Yan Huang","doi":"10.2174/1568009623666230712095021","DOIUrl":null,"url":null,"abstract":"Objective: This review describes the comprehensive portrait of tumor microenvironment (TME). Additionally, we provided a panoramic perspective on the transformation and functions of the diverse constituents in TME, and the underlying mechanisms of drug resistance, beginning with the immune cells and metabolic dynamics within TME. Lastly, we summarized the most auspicious potential therapeutic strategies.Results: TME is a unique realm crafted by malignant cells to withstand the onslaught of endogenous and exogenous therapies. Recent research has revealed many small-molecule immunotherapies exhibiting auspicious outcomes in preclinical investigations. Furthermore, some pro-immune mechanisms have emerged as a potential avenue. With the advent of nanosystems and precision targeting, targeted therapy has now transcended the \"comfort zone\" erected by cancer cells within TME.Conclusion: The ceaseless metamorphosis of TME fosters the intransigent resilience and proliferation of tumors. However, existing therapies have yet to surmount the formidable obstacles posed by TME. Therefore, scientists should investigate potential avenues for therapeutic intervention and design innovative pharmacological and clinical technologies.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1568009623666230712095021","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This review describes the comprehensive portrait of tumor microenvironment (TME). Additionally, we provided a panoramic perspective on the transformation and functions of the diverse constituents in TME, and the underlying mechanisms of drug resistance, beginning with the immune cells and metabolic dynamics within TME. Lastly, we summarized the most auspicious potential therapeutic strategies.

Results: TME is a unique realm crafted by malignant cells to withstand the onslaught of endogenous and exogenous therapies. Recent research has revealed many small-molecule immunotherapies exhibiting auspicious outcomes in preclinical investigations. Furthermore, some pro-immune mechanisms have emerged as a potential avenue. With the advent of nanosystems and precision targeting, targeted therapy has now transcended the "comfort zone" erected by cancer cells within TME.

Conclusion: The ceaseless metamorphosis of TME fosters the intransigent resilience and proliferation of tumors. However, existing therapies have yet to surmount the formidable obstacles posed by TME. Therefore, scientists should investigate potential avenues for therapeutic intervention and design innovative pharmacological and clinical technologies.

查看原文本刊更多论文

肿瘤微环境异质性、潜在治疗途径和新兴疗法。

目的：这篇综述全面描述了肿瘤微环境（TME）。此外，我们还从肿瘤微环境中的免疫细胞和代谢动态入手，全景式地阐述了肿瘤微环境中各种成分的转变和功能，以及耐药性的潜在机制。最后，我们总结了最有利的潜在治疗策略：TME是恶性细胞为抵御内源性和外源性疗法的冲击而精心打造的独特领域。最近的研究发现，许多小分子免疫疗法在临床前研究中表现出良好的疗效。此外，一些促免疫机制已成为一种潜在的途径。随着纳米系统和精准靶向技术的出现，靶向治疗现已超越了癌细胞在TME内建立的 "舒适区"：TME的不断蜕变助长了肿瘤顽强的生命力和增殖。然而，现有疗法仍无法克服 TME 带来的巨大障碍。因此，科学家应研究治疗干预的潜在途径，并设计创新的药物和临床技术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current cancer drug targets 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

105

审稿时长

1 months

期刊介绍： Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.